Craig R. Lee

CYP2C19 genotype-guided P2Y12 inhibitor therapy optimization in patients at high bleeding risk: existing evidence and future directions

ABSTRACT Introduction Use of CYP2C19 genotype to optimize oral P2Y12 inhibitor therapy can reduce major adverse cardiovascular events (MACE) after percutaneous intervention (PCI) in acute coronary syndrome (ACS) patients. Interest in guided strategies to reduce bleeding risk by ‘de-escalation’ of antiplatelet therapy,...